Changes in Peripheral Blood Neutrophils, Lymphocytes and IL-10 in Children with Kawasaki Disease from Different Age Groups Undergoing Intravenous Immunoglobulin: A Retrospective Study
Table 1
Clinical and biochemical characteristics of the Kawasaki disease children.
Characteristics
Total
0-1 year
1-2 years
2-3 year
3-4 years
Above 4 years
value
Patients ()
50
6
14
16
5
9
—
Gender (m)( (%))
27 (54)
4 (66.7)
9 (64.3)
8 (50)
2 (40)
4 (44.44)
0.77
Age (months)
28 (16-42.25)
8 (3.00-11.00)
16.5 (15-19.25)
29.5 (26.50-31)
43 (41.5-45)
64 (58.5-75.5)
<0.01
Body weight (kg)
13.38 (10.75-16.63)
7.8 (7.37-9.13)
11.03 (10-12)
14 (13-15)
15 (14.4-16.6)
18 (17.75-20.75)
<0.01
Aspirin dosage (mg/kg.dose)
11.11 (10.00-12.50)
10.27 (8.39-11.42)
12.5 (10-13.59)
11.22 (10.09-12.41)
11.63 (8.33-13.50)
11.11 (9.76-11.27)
0.38
Aspirin frequency (doses/day)
3
3
3
3
3
3
0.23
Duration of high dose aspirin (days)
4 (4-5)
4 (3.75-6.75)
4 (4-5)
5 (3.25-5.75)
3 (2.5-5.0)
4.0 (3.5-4.5)
0.61
IgG dosing (g/kg)
1.96 (1.90-2.00)
1.97 (1.84-2.03)
1.95 (1.86-2.05)
1.96 (1.92-2)
2 (2-2.02)
1.94 (1.49-1.97)
0.37
The reduced extent of neutrophil percentage (%)
0.87
The increased extent of lymphocyte percentage (%)
0.76
The decreased IL-10 (pg/ml)
15.05 (6.32-52.33)
10.7 (8.18-49.38)
42.65 (14.98-75.18)
11.85 (2.49-31.78)
14.5 (0.7-63.32)
12.2 (3.83-24.35)
0.35
The absolute count of CD19+ B cell(cells/μl)
857.2 (520.44-1285.46)
1043.83 (419.02-1736.44)
1176.9 (1019.37-1954.14)
579.29 (432.90-997.5)
1220.95 (918.06-1322.56)
534.64 (233.96-743.67)
<0.01
CD19+ B cell (%)
0.305
NLR before IVIG
<0.01
NLR after IVIG
0.077
Values are expressed as , number, or median (1-3). NLR: neutrophil lymphocyte ratio.
